CN105254626B - 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用 - Google Patents

一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用 Download PDF

Info

Publication number
CN105254626B
CN105254626B CN201510611722.5A CN201510611722A CN105254626B CN 105254626 B CN105254626 B CN 105254626B CN 201510611722 A CN201510611722 A CN 201510611722A CN 105254626 B CN105254626 B CN 105254626B
Authority
CN
China
Prior art keywords
cdcl
nmr
present
diindyl
hexahydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510611722.5A
Other languages
English (en)
Other versions
CN105254626A (zh
Inventor
刘雄利
张文会
黄俊飞
陆毅
张敏
周英
俸婷婷
余章彪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN201510611722.5A priority Critical patent/CN105254626B/zh
Publication of CN105254626A publication Critical patent/CN105254626A/zh
Application granted granted Critical
Publication of CN105254626B publication Critical patent/CN105254626B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用，本发明以相应的由相应的3‑单取代氧化吲哚1与丙烯酸酯2先发生Michael加成反应，生成中间体3，然后中间体3与甲胺发生酰胺化反应，生成中间体4，最后中间体4通过与四氢化铝锂发生氢化还原环化反应生成最终产物六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物。它是一类重要的抗肿瘤活性先导化合物，对药物筛选和制药行业具有重要的应用价值，本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。本发明针对这些衍生物对三种肿瘤细胞株如人肺癌细胞(A549)、人前列腺(PC‑3)以及人白血病细胞(K562)所进行的肿瘤生长抑制活性筛选。这些衍生物发现具有一定的抑制肿瘤细胞生长活性，可预期作为抗肿瘤药物或抗肿瘤药物中间体用途。

Description

一种六氢吡啶-2,3-并吲哚-2-酮类化合物及其制备方法及 应用
技术领域
本发明涉及化学技术领域，尤其是一种六氢吡啶-2,3-并吲哚-2-酮类化合物及其制备方法及应用。
背景技术
六氢吡啶-2,3-并吲哚-2-酮骨架广泛存在于许多具有重要生物活性的吲哚生物碱中，例如Neoxaline(I)1979年从一个日本曲霉培养液fg-551中分离出来，测试显示具有抗癌活性，机制研究显示；该化合物能抑制细胞增殖，在细胞分裂G期阻滞细胞进程；至目前为止，10种相关的天然产物9-epi-neoxaline(II),oxaline(III),the glandicolins(IV,V),和the meleagrins(VI-X)也已经在对青霉菌的培养液中分离出来，测试显示也都具有抗癌活性；Kapakahine A(XI)也包含六氢吡啶-2,3-并吲哚-2-酮骨架，具有抗肿瘤活性(如图7所示)。在这个背景下，鉴于含六氢吡啶-2,3-并吲哚-2-酮天然产物具有潜在的生物活性，因此，合成一系列具有六氢吡啶-2,3-并吲哚-2-酮骨架化合物可能会产生一系列结构和活性上有意义的新化合物分子，它们的合成可以为生物活性筛选提供化合物源，对寻找新型的抗肿瘤活性先导化合物具有重要的意义。
发明内容
本发明的目的是：提供一种新型六氢吡啶-2,3-并吲哚-2-酮类化合物及其制备方法及应用，它是一类重要的抗肿瘤活性先导化合物，对 药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。
本发明是这样实现的新型六氢吡啶-2,3-并吲哚-2-酮类化合物，该化合物具有如通式(Ⅰ)所示的结构：
式中，R2为烷基或芳基；R3为H或烷基或卤素。
六氢吡啶-2,3-并吲哚-2-酮类化合物的制备方法，其特征在于：由相应的3-单取代氧化吲哚1与丙烯酸酯2先发生Michael加成反应，生成中间体3，然后中间体3氮原子脱保护基团Boc得到了中间体3-1，然后中间体3-1氮原子上保护基甲基得到中间体3-2,中间体3-2再与甲胺发生酰胺化反应，生成中间体3-3，最后中间体3-3通过与四氢化铝锂发生氢化还原环化反应生成最终产物六氢吡啶-2,3-并吲哚-2-酮类化合物。
本发明合成路线如下：
(1)20mol％CF3COOH,rt,2h；(2)干燥的溶剂DMF,1.2eq NaH,1.5eq CH3I,0℃,8h；(3)3.0mL MeOH,3.0mL MeNH2(30％in MeOH),rt,48h；(4)干燥的溶剂THF，10eqLiAlH4,0℃,5h.
其中，R1为烷基或Boc；R2为烷基或芳基；R3为H或烷基或卤素；R4为烷基。
通过采用上述技术方案，以相应的3-单取代氧化吲哚1与丙烯酸酯2先发生Michael加成反应，生成中间体3，然后中间体3氮原子脱保护基团Boc得到了中间体3-1，然后中间体3-1氮原子上保护基甲基得到中间体3-2,中间体3-2再与甲胺发生酰胺化反应，生成中间体3-3，最后中间体3-3通过与四氢化铝锂发生氢化还原环化反应生成最终产物六氢吡啶-2,3-并吲哚-2-酮类化合物。它是一类重要的抗肿瘤活性先导化合物，对药物筛选和制药行业具有重要的应用价值，本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。
附图1-6为本发明的实施例化合物4a-4c的核磁共振谱图；
附图7为本发明的技术背景说明图。
附图8为本发明化合物4k的X单晶衍射说明图。
具体实施方式
(一)、代表性反应中间体3的合成制备
化合物3aa:在反应瓶中加入134mg N-Boc-3-苯基氧化吲哚1a(0.4mmol)和97mg丙烯酸苄酯2a(0.6mmol)，溶解在5.0mL的二氯甲烷中，加入催化剂TBAB(10mol％,12.8mg)andK2CO3(20mol％,11.0mg)，在氩气保护下室温搅 拌反应24h,TLC检测完全后，直接经硅胶柱层析[洗脱剂：V(乙酸乙酯):V(石油醚)＝10:1～5:1]，分离得到黄色液体3aa 173mg,总产率92％。核磁共振和高分辨质谱测试结果如下：Light orange oil；Yield 92％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),1.97-2.14(m,1H),2.21-2.36(m,1H),2.48-2.65(m,1H),2.76-2.96(m,1H),4.84-5.19(m,2H),7.21-7.25(d,J＝4.0Hz,2H),7.29-7.34(m,11H),7.79-8.10(d,J＝4.0Hz,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.7,32.9,56.0,66.5,84.6,115.4,124.7,127.0,127.7,128.3,128.5,128.7,128.8,129.8,135.5,139.2,139.9,149.1,172.2,176.2；HRMS(ESI-TOF)m/z:Calcd.for C29H29NNaO5[M+Na]+:494.1943；Found:494.1946.
通过实施例制备的化合物3ba～3b’b’的制备方法同化合物3aa，投料比与化合物3aa相同，可得到化合物3ba～3b’b’，反应产率见表1，但需强调的是实施例旨在阐述而不是限制本发明的范围。本发明的化合物不限于表1与表2所表示的内容。
表1为制备六氢吡啶-2,3-并吲哚-2-酮类化合物中间体3的化学结构
表2为制备六氢吡啶-2,3-并吲哚-2-酮类化合物中间体3的化学结构
本实施例制备中间体化合物3ba:Light orange oil；Yield 90％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),2.06(d,J＝11.6Hz,1H),2.21-2.36(m,1H),2.29(s,3H),2.49-2.61(m,1H),2.78-2.89(m,1H),5.01(m,2H),7.10(d,J＝8.1Hz,2H),7.71-7.23(m,4H),7.23-7.39(m,6H),7.93(d,J＝8.2Hz,1H)；13C NMR(CDCl3,100MHz)δ:20.1,28.0,29.7,32.8,55.7,66.4,84.4,115.3,124.7,126.8,128.2,128.5,128.7,129.3,130.0,135.5,136.2,137.5,139.9,149.1,172.2,176.3；HRMS(ESI-TOF)m/z:Calcd.for C30H31NNaO5[M+Na]+:508.2099；Found:508.2097.
本实施例制备中间体化合物3ca:Light orange oil；Yield 87％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),2.05-2.10(m,1H),2.23-2.35(m,1H),2.25(s,6H),2.52-2.62(m,1H),2.79-2.91(m,1H),4.97-5.07(m,2H),6.75-7.00(s,2H),7.19-7.40(m,9H),7.90-7.96(d,J＝8.0Hz,1H)；13C NMR(CDCl3,100MHz)δ:21.4,27.5,28.0,29.7,32.7,55.9,66.4,84.5,115.3,124.3,124.7,128.3,128.5,128.6,129.5,130.2,131.1,138.2,139.1,139.8,149.2,172.3,176.4；HRMS(ESI-TOF)m/z:Calcd.for C31H33NNaO5[M+Na]+:522.2256；Found:522.2259.
本实施例制备中间体化合物3da:Light orange oil；Yield 88％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),2.02-2.04(m,1H),2.26(dd,J＝4.9,11.8Hz,1H),2.30(s,3H),2.53-2.57(m,1H),2.82-2.86(m,1H),5.00-5.04(m,2H),7.07(d,J＝7.7Hz,2H),7.11-7.40(m,10H),7.93(d,J＝8.2Hz,1H)；13C NMR(CDCl3,100MHz)δ:21.6,28.9,29.7,32.8,55.9,66.5,84.5,115.3,124.0,124.7,127.6,128.3,128.5,128.6,128.7,130.0,135.6,138.4,139.1,139.9,149.1,172.2,176.3；HRMS(ESI-TOF)m/z:Calcd.for C30H31NNaO5[M+Na]+:508.2099；Found:508.2098.
本实施例制备中间体化合物3ea:Light orange oil；Yield 86％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),2.05-2.10(m,1H),2.23-2.35(m,1H),2.35(s,3H),2.51-2.62(m,1H),2.79-2.91(m,1H),4.97-5.07(m,2H),6.99(s,1H),7.20-7.23(m,1H),7.19-7.40(m,10H),7.90-7.96(m,1H)；13C NMR(CDCl3,100MHz)δ:21.1,28.0,29.7,32.7,56.0,66.4,84.4,115.1,125.1,127.0,127.7,128.3,128.4,128.5,128.7,129.3,129.8,134.4,135.5,137.5,139.4,149.1,172.3,176.4；HRMS(ESI-TOF)m/z:Calcd.for C30H31NNaO5[M+Na]+:508.2099；Found:508.2097.
本实施例制备中间体化合物3fa:Light orange oil；Yield 85％；1H NMR(CDCl3,400MHz)δ:1.60(s,9H),2.04-2.10(m,1H),2.22-2.28(m,1H),2.30(s,3H),2.34(s,3H),2.46-2.58(m,1H),2.78-2.88(m,1H),4.98-5.09(m,2H),6.98(s,1H),7.02-7.39(m,10H),7.74-7.85(m,1H)；13C NMR(CDCl3,100MHz)δ:20.9,21.1,28.0,29.7,32.6,55.7,66.4,84.3,115.1,125.1,126.8,128.3,128.5,129.2,129.4,130.0,134.4,135.6,136.5,137.5,137.6,149.2,172.3,176.5；HRMS(ESI-TOF)m/z:Calcd.for C31H33NNaO5[M+Na]+:522.2256；Found:522.2257.
本实施例制备中间体化合物3ga:Light orange oil；Yield 82％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),2.00-2.11(m,1H),2.23-2.35(m,1H),2.46-2.59(m,1H),2.78-2.91(m,1H),4.98-5.11(m,2H),6.90-6.95(m,1H),7.03-7.11(m,1H),7.20-7.40(m,10H),7.90-7.97(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.6,32.7,56.2,66.6,84.8,112.1(d,JCF＝19.4Hz),115.4(d,JCF＝18.0Hz),116.8(d,JCF＝6.2Hz),126.8,128.0,128.3,128.6,128.8,135.4,135.8,138.6,149.0,160.0(d,JCF＝194.6Hz),172.0,175.8；HRMS(ESI-TOF)m/z:Calcd.for C29H28FNNaO5[M+Na]+:512.1849；Found:512.1848.
本实施例制备中间体化合物3ha:Light orange oil；Yield 81％；1H NMR(CDCl3,400MHz)δ:1.60(s,9H),1.99-2.11(m,1H),2.21-2.33(m,1H),2.30(s,3H),2.44-2.58(m,1H),2.76-2.92(m,1H),4.93-5.11(m,2H),6.89-6.94(m,1H),6.89-7.00(m,10H),7.91-7.98(m,1H)；13C NMR(CDCl3,100MHz)δ:20.9,28.0,29.6,32.6,55.9,66.5,84.7,112.0(d,JCF＝19.4Hz),115.3(d,JCF＝18.1Hz),116.7(d,JCF＝6.3Hz),126.7,128.3,128.5,129.5,135.5,135.7,135.8,137.8,149.1,160.0(d,JCF＝194.5Hz),172.0,175.9；HRMS(ESI-TOF)m/z:Calcd.for C30H30FNNaO5[M+Na]+:526.2005；Found:526.2005.
本实施例制备中间体化合物3ia:Light orange oil；Yield 82％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),2.07(dd,J＝4.8,11.6Hz,1H),2.19-2.30(m,1H),2.31(s,3H),2.47-2.59(m,1H),2.82-2.87(m,1H),5.04(d,J＝2.4Hz,2H),6.92(dd,J＝2.7,7.7Hz,1H),7.00-7.38(m,10H),7.94(dd,J＝4.6,9.0Hz,1H)；13C NMR(CDCl3,100MHz)δ:21.6,28.0,29.6,32.6,56.1,66.6,84.7,112.1(d,JCF＝24.1Hz),115.4(d,JCF＝22.6Hz),116.7(d,JCF＝7.8Hz),123.8,127.4,128.3,128.5,128.6,128.8,135.5,138.5,138.6,149.1,160.0(d,JCF＝243.1Hz),172.0,175.8；HRMS(ESI-TOF)m/z:Calcd.for C30H30FNNaO5[M+Na]+:526.2005；Found:526.2007.
本实施例制备中间体化合物3ja:Light orange oil；Yield 85％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),1.99-2.04(m,1H),2.26(s,6H),2.22-2.31(m,1H),2.46-2.57(m,1H),2.78-2.89(m,1H),4.99-5.09(m,2H),6.85-6.94(m,4H),7.02-.10(m,1H),7.21-7.39(m,5H),7.87-7.98(m,1H)；13C NMR(CDCl3,100MHz)δ:21.4,28.0,29.6,32.5,56.1,66.6,84.7,112.0(d,JCF＝19.4Hz),115.3(d,JCF＝18.0Hz),116.7(d,JCF＝6.2Hz),124.5,128.3,128.6,129.7,132.2,135.5,135.8,138.4,138.5,149.1,160.0(d,JCF＝194.4Hz),172.1,176.0；HRMS(ESI-TOF)m/z:Calcd.for C31H32FNNaO5[M+Na]+:540.2162；Found:540.2165.
本实施例制备中间体化合物3ka:Light orange oil；Yield 87％；1H NMR(CDCl3,400MHz)δ:1.56(s,9H),1.86-1.99(m,1H),2.11-2.33(m,2H),2.40-2.51(m,1H),2.97(d,J＝13.1Hz,1H),3.12(d,J＝13.1Hz,1H),3.68(s,3H),4.99(m,2H),6.55-6.61(m,2H),6.67-6.74(m,2H),7.07-7.36(m,8H),7.59(d,J＝8.0Hz,1H)； 13C NMR(CDCl3,100MHz)δ:27.9,29.5,31.7,44.6,54.3,55.0,66.3,84.0,123.4, 124.1,126.7,128.2,128.3,128.5,128.8,130.8,135.6,139.8,148.6,158.3,172.3,177.6；HRMS(ESI-TOF)m/z:Calcd.forC31H33NNaO6[M+Na]+:538.2205；Found:538.2210.
本实施例制备中间体化合物3lb:Light orange oil；Yield 93％；1H NMR(CDCl3,400MHz)δ:1.56(s,9H),1.84-1.94(m,1H),2.09-2.19(m,1H),2.23-2.35(m,1H),2.41-2.51(m,1H),2.98-3.05(m,1H),3.14-3.22(m,1H),3.55(s,3H),6.76-6.81(m,2H),6.99-7.29(m,6H),7.56-7.61(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.4,31.9,45.6,51.6,54.3,84.0,114.9,123.4,124.2,126.8,127.7,128.4,128.7,129.9,134.7,139.9,148.7,173.0,177.5；HRMS(ESI-TOF)m/z:Calcd.for C24H27NNaO5[M+Na]+:432.1786；Found:432.1789.
本实施例制备中间体化合物3mb:Light orange oil；Yield 87％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),1.80-1.90(m,1H),2.07-2.16(m,1H),2.21-2.31(m,1H),2.39-2.50(m,1H),3.06-3.12(m,1H),3.25-3.32(m,1H),3.51(s,3H),3.54(s,3H),6.57-6.61(m,1H),6.69-6.75(m,1H),6.92-6.97(m,1H),6.98-7.11(m,3H),7.11-7.20(m,1H),7.60-7.65(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.4,31.9,38.2,51.5,53.5,54.5,83.9,109.8,114.3,119.7,123.4,123.8,124.1,127.9,128.2,129.0,131.3,139.5,149.0,157.3,173.0,177.9；HRMS(ESI-TOF)m/z:Calcd.for C25H29NNaO6[M+Na]+:462.1892；Found:462.1895.
本实施例制备中间体化合物3nb:Light orange oil；Yield 84％；1H NMR(CDCl3,400MHz)δ:1.62(s,9H),1.79-1.90(m,1H),2.07-2.17(m,1H),2.21-2.32(m,1H),2.40-2.52(m,1H),3.11-3.16(m,1H),3.24-3.29(m,1H),3.54(s,3H),3.67(s,3H),3.74(s,3H),6.48-6.53(m,1H),6.66-6.71(m,1H),6.75-6.80(m,1H),7.00-7.09(m,2H),7.13-7.29(m,1H),7.65-7.69(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.4,32.6,37.5,51.5,53.5,55.7,60.4,84.0,111.6,114.5,122.9,124.0,124.1,128.1,128.9,129.2,139.6,147.7,149.0,152.3,173.0,178.0；HRMS(ESI-TOF)m/z:Calcd.for C26H31NNaO7[M+Na]+:492.1998；Found:492.1997.
本实施例制备中间体化合物3ob:Light orange oil；Yield 88％；1H NMR(CDCl3,400MHz)δ:1.55(s,9H),1.88-1.97(m,1H),2.10-2.20(m,1H),2.23-2.32(m,1H), 2.40-2.49(m,1H),2.92-3.01(m,1H),3.10-3.17(m,1H),3.55(s,3H),3.58(s,3H),3.75(s,3H),6.15-6.21(m,1H),6.37-6.44(m,1H),6.53-6.58(m,1H),7.14-7.30(m,3H),7.57-7.61(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.4,32.0,45.2,51.5,54.5,55.5,55.7,84.0,110.5,112.8,115.0,122.1,123.3,124.0,127.3,128.4,129.1,140.1,147.8,148.0,148.6,172.8,177.4；HRMS(ESI-TOF)m/z:Calcd.for C26H31NNaO7[M+Na]+:492.1998；Found:492.1998.
本实施例制备中间体化合物3pb:Light orange oil；Yield 84％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),1.95-1.81(m,1H),2.20-2.06(m,1H),2.34-2.21(m,1H),2.53-2.40(m,1H),3.11-3.03(m,1H),3.31-3.24(m,1H),3.48(s,3H),3.54(s,3H),3.63(s,3H),6.54-6.48(m,2H),6.62-6.58(m,1H),7.08-7.01(m,2H),7.29-7.12(m,1H),7.67-7.60(m,1H)；13CNMR(CDCl3,100MHz)δ:28.0,29.4,32.1,38.1,51.5,53.6,55.1,55.5,83.9,110.8,113.2,114.3,116.5,123.5,124.1,124.6,128.0,129.0,139.6,149.0,151.5,152.7,173.0,177.8；HRMS(ESI-TOF)m/z:Calcd.for C26H31NNaO7[M+Na]+:492.1998；Found:492.1995.
本实施例制备中间体化合物3qb:Yellow oil；Yield 81％；1H NMR(CDCl3,400MHz)δ:1.61(s,9H),1.78-1.89(m,1H),2.06-2.16(m,1H),2.18-2.29(m,1H),2.37-2.49(m,1H),2.97-3.05(m,1H),3.16-3.24(m,1H),3.48(s,3H),3.54(s,3H),3.71(s,3H),6.18-6.20(m,1H),6.24-6.28(m,1H),6.82-6.86(m,1H),6.97-7.07(m,2H),7.13-7.20(m,1H),7.61-7.69(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.4,31.7,37.8,51.5,53.7,54.6,55.1,83.8,97.8,103.4,114.4,116.1,123.4,124.1,127.9,129.2,131.7,139.5,149.0,158.3,159.7,173.0,177.9；HRMS(ESI-TOF)m/z:Calcd.for C26H31NNaO7[M+Na]+:492.1998；Found:492.1996.
本实施例制备中间体化合物3rb:Yellow oil；Yield 90％；1H NMR(CDCl3,400MHz)δ:1.57(s,9H),1.84-1.94(m,1H),2.07-2.20(m,4H),2.22-2.32(m,1H),2.39-2.52(m,1H),2.92-3.00(m,1H),3.10-3.16(m,1H),3.55(s,3H),6.52-6.65(m,2H),6.85-6.95(m,2H),7.06-7.29(m,3H),7.55-7.62(m,1H)；13C NMR(CDCl3,100MHz)δ:21.1,28.0,29.4,31.8,45.4,51.5,54.2,83.9,114.7,123.4,124.0,126.8,127.4,127.4,128.3,128.8,130.5,134.6,137.1,139.9,148.7,172.9,177.4；HRMS(ESI-TOF)m/z:Calcd.for C25H29NNaO5[M+Na]+:446.1943；Found:446.1947.
本实施例制备中间体化合物3sb:Yellow oil；Yield 85％；1H NMR(CDCl3,400MHz)δ:1.58(s,9H),1.79-1.88(m,1H),1.97(s,3H),2.06-2.15(m,1H),2.28-2.37(m,1H),2.45-2.54(m,1H),3.06-3.10(m,1H),3.15-3.21(m,1H),3.55(s,3H),6.78-6.82(m,1H),6.87-7.11(m,5H),7.21-7.27(m,1H),7.66-7.71(m,1H)；13CNMR(CDCl3,100MHz)δ:19.7,28.0,29.4,31.4,41.4,51.5,53.6,84.0,114.8,123.7,124.0,125.2,126.9,128.5,128.7,130.3,130.5,133.3,137.2,139.8,148.8,172.9,177.7；HRMS(ESI-TOF)m/z:Calcd.forC25H29NNaO5[M+Na]+:446.1943；Found:446.1945.
本实施例制备中间体化合物3tb:Yellow oil；Yield 89％；1H NMR(CDCl3,400MHz)δ:1.56(s,9H),1.83-1.93(m,1H),2.08-2.17(m,1H),2.20(s,3H),2.23-2.31(m,1H),2.34-2.49(m,1H),2.95-3.15(m,2H),3.55(s,3H),6.65-6.78(m,2H),6.82-6.89(m,2H),7.10-7.17(m,2H),7.21-7.24(m,1H),7.59-7.61(m,1H)；13CNMR(CDCl3,100MHz)δ:20.9,27.9,29.4,31.8,45.1,51.5,54.2,83.9,109.6,114.8,122.1,123.4,124.1,128.0,128.3,128.8,129.7,129.8,131.6,136.2,139.8,148.7,173.0,177.6；HRMS(ESI-TOF)m/z:Calcd.for C25H29NNaO5[M+Na]+:446.1943；Found:446.1946.
本实施例制备中间体化合物3ub:Yellow oil；Yield 83％；1H NMR(CDCl3,400MHz)δ:1.12-1.16(m,6H),1.56(s,9H),1.83-1.92(m,1H),2.08-2.17(m,1H),2.22-2.31(m,1H),2.41-2.50(m,1H),2.72-2.78(m,1H),2.97-3.15(m,2H),3.55(s,3H),6.66-6.74(m,2H),6.86-6.93(m,2H),7.09-7.29(m,3H),7.57-7.61(m,1H)；13CNMR(CDCl3,100MHz)δ:23.8,23.9,28.0,29.4,31.7,33.5,45.2,51.6,54.2,83.9,114.8,123.4,124.1,125.6,128.3,128.9,129.8,131.9,139.8,147.3,148.6,173.0,177.5；HRMS(ESI-TOF)m/z:Calcd.forC27H33NNaO5[M+Na]+:474.2256；Found:474.2261.
本实施例制备中间体化合物3vb:Light yellow oil；Yield 88％；1H NMR(CDCl3,400MHz)δ:1.21(s,9H),1.56(s,9H),1.83-1.92(m,1H),2.09-2.19(m,1H),2.22-2.32(m,1H),2.39-2.50(m,1H),2.97-3.03(m,1H),3.08-3.14(m,1H),3.55(s,3H),6.67-6.74(m,2H),7.04-7.29(m,5H),7.57-7.63(m,1H)；13C NMR(CDCl3,100MHz)δ:28.0,29.5,31.2,31.7,34.3,45.1,51.6,54.2,83.9,114.8,123.5,124.1,124.5, 128.3,129.0,129.6,131.6,139.9,148.7,149.6,173.0,177.5；HRMS(ESI-TOF)m/z:Calcd.for C28H35NNaO5[M+Na]+:488.2412；Found:488.2416.
本实施例制备中间体化合物3wb:Light yellow oil；Yield 80％；1H NMR(CDCl3,400MHz)δ:1.53(s,9H),1.85-1.95(m,1H),2.10-2.20(m,1H),2.25-2.36(m,1H),2.43-2.53(m,1H),3.04-3.12(m,1H),3.28-3.19(m,1H),3.56(s,3H),6.85-6.93(m,2H_),7.16-7.33(m,5H),7.52-7.60(m,1H)；13C NMR(CDCl3,100MHz)δ:27.90,29.33,32.00,45.17,51.63,54.16,84.33,115.01,122.95,123.20,124.40,124.52,125.12,128.20,128.79,128.97,129.23,130.09,138.87,139.84,148.34,172.77,177.00；HRMS(ESI-TOF)m/z:Calcd.forC25H26F3NNaO5[M+Na]+:500.1660；Found:500.1663.
本实施例制备中间体化合物3xb:Light yellow oil；Yield 80％；1H NMR(CDCl3,400MHz)δ:1.78(dd,J＝11.0,5.2Hz,1H),1.96(s,3H),1.97-2.09(m,1H),2.20(s,3H),2.32(dd,J＝11.1,5.3Hz,1H),2.40(dd,J＝11.0,5.4Hz,1H),3.00-3.13(m,5H),3.53(s,3H),6.71-6.78(m,4H),6.90-6.95(m,2H),7.18-7.24(m,1H)；13C NMR(CDCl3,100MHz)δ:19.8,20.8,25.9,29.3,31.3,39.4,51.5,53.3,107.8,122.0,124.0,125.8,128.1,130.0,130.3,131.0,136.0,136.8,143.7,173.1,179.0；HRMS(ESI-TOF)m/z:Calcd.for C22H25NNaO3[M+Na]+:374.1732；Found:374.1733.
本实施例制备中间体化合物3yb:Yellow oil；Yield 86％；1H NMR(CDCl3,400MHz)δ:1.74-1.87(m,1H),1.99-2.11(m,1H),2.21-2.26(m,1H),2.36-2.42(m,1H),2.93(d,J＝13.3Hz,1H),3.08(s,3H),3.33(d,J＝13.3Hz,1H),3.53(s,3H),3.57(s,3H),3.67(s,3H),3.78(s,3H),6.25(s,1H),6.44(s,1H),6.63(d,J＝7.7Hz,1H),6.92-6.99(m,1H),7.07-7.18(m,2H)；13C NMR(CDCl3,100MHz)δ:25.9,29.4,31.5,35.8,51.5,53.7,55.7,55.8,56.1,96.5,107.4,114.2,115.6,121.5,124.3,127.8,130.1,141.8,143.6,147.9,151.4,173.2,179.1；HRMS(ESI-TOF)m/z:Calcd.for C23H27NNaO6[M+Na]+:436.1736；Found:436.1738.
本实施例制备中间体化合物3zb:Yellow oil；Yield 81％；1H NMR(CDCl3,400MHz)δ:1.74-1.86(m,1H),2.00-2.10(m,1H),2.20-2.30(m,1H),2.34-2.43(m,1H),2.96-3.01(m,1H),3.11(s,3H),3.19-3.25(m,1H),3.53(s,3H),3.62(s,3H),3.68(s, 3H),3.76(s,3H),6.38-6.43(m,1H),6.59-6.67(m,2H),6.91-6.98(m,1H),7.02-7.08(m,1H),7.10-7.17(m,1H)；13C NMR(CDCl3,100MHz)δ:26.0,29.3,31.7,36.1,51.5,53.5,55.8,60.5,60.6,106.1,107.4,122.0,124.5,124.9,127.8,130.0,141.6,143.6,152.1,152.3,173.3,179.1；HRMS(ESI-TOF)m/z:Calcd.for C23H27NNaO6[M+Na]+:436.1736；Found:436.1739.
本实施例制备中间体化合物3a'b:Yellow oil；Yield 78％；1H NMR(CDCl3,400MHz)δ:1.81-1.85(m,1H),2.05-2.08(m,1H),2.25-2.29(m,1H),2.37-2.45(m,1H),2.98(s,3H),3.01(d,J＝13.0Hz,1H),3.16(d,J＝12.9Hz,1H),3.55(s,3H),6.46-6.53(m,1H),6.62(d,J＝7.7Hz,2H),6.71-6.76(m,1H),7.10-7.10(m,2H),7.13-7.28(m,2H)；13C NMR(CDCl3,100MHz)δ:25.8,29.3,31.7,43.7,43.8,51.6,53.8,108.0,113.4(d,JCF＝20.8Hz),116.5(d,JCF＝21.3Hz),122.4,123.5,125.5(d,JCF＝2.8Hz),128.4,128.8(d,JCF＝8.3Hz),129.5,138.0,138.1,143.7,162.0(d,JCF＝243.6Hz),173.0,178.0；HRMS(ESI-TOF)m/z:Calcd.for C20H20FNNaO3[M+Na]+:364.1324；Found:364.1325.
本实施例制备中间体化合物3b'b:Light yellow oil；Yield 76％；1H NMR(CDCl3,400MHz)δ:1.84-1.90(m,1H),2.04-2.13(m,1H),2.24-2.30(m,1H),2.35-2.41(m,1H),3.03(s,3H),3.25(d,J＝11.6Hz,1H),3.41(d,J＝11.6Hz,1H),3.54(m,3H),6.54(s,1H),6.68-6.72(m,2H),6.92(d,J＝3.6Hz,1H),7.07-7.10(m,1H),7.18(d,J＝5.6Hz,1H),7.23-7.27(m,1H)；13C NMR(CDCl3,100MHz)δ:26.0,29.3,31.7,37.9,51.6,53.7,108.0,122.5,123.5,124.1,126.1,126.8,128.5,129.8,137.2,144.2,173.0,178.1；HRMS(ESI-TOF)m/z:Calcd.for C18H19NNaO3S[M+Na]+:352.0983；Found:352.0984.
(二)、产物六氢吡啶-2,3-并吲哚-2-酮类化合物4的合成制备
中间体化合物3-1:在反应瓶中加入化合物3(0.5mmol)，溶解在5.0mL CaH2刚干燥过的二氯甲烷中，加入CF3COOH(20mol％,11.4mg)，在室温搅拌反应2h, TLC检测完全后，直接经硅胶柱层析[洗脱剂：V(乙酸乙酯):V(石油醚)＝10:1～5:1]，分离得到黄色液体3-1。
中间体化合物3-2:在反应瓶中加入中间体化合物3-1(0.45mmol)，溶解在NaOH干燥过的5.0mL的DMF中，加入NaH(60％dispersion in mineral oil,1.2eq,21.6mg)，在0℃下搅拌反应10分钟后，再加入CH3I(1.5eq,95.9mg)，在0℃下搅拌反应8h,TLC检测完全后，直接经硅胶柱层析[洗脱剂：V(乙酸乙酯):V(石油醚)＝5:1]，分离得到黄色液体3-2。
中间体化合物3-3:在反应瓶中加入中间体化合物3-2(0.40mmol)，溶解在3.0mL的MeOH中，加入MeNH2(3mL,30％in MeOH)，在室温下搅拌反应48h后，TLC检测完全后，减压蒸干溶剂，溶解在二氯甲烷中经硅胶柱层析[洗脱剂：V(乙酸乙酯):V(石油醚)＝5:1]，分离得到黄色液体3-3。
终产物4a-4z:在反应瓶中加入中间体化合物3-3(0.4mmol)，溶解在Na干燥过的6.0mL的THF中，在0℃下加入LiAlH4(10.0eq,4.0mmol,152mg)，在0℃下搅拌反应5h后，TLC检测完全后，用饱和的氯化铵萃灭反应，乙酸乙酯萃取多次后，硫酸钠干燥后，减压蒸干溶剂，二氯甲烷溶解经硅胶柱层析[洗脱剂：V(乙酸乙酯):V(石油醚)＝3:1]，分离得到黄色液体或固体4a-4z。
通过实施例制备的化合物4a-4z,反应产率见表2，但需强调的是实施例旨在阐述而不是限制本发明的范围。本发明的化合物不限于表2和表3所表示的内容。
表2为制备六氢吡啶-2,3-并吲哚-2-酮类化合物4的化学结构
表3为制备六氢吡啶-2,3-并吲哚-2-酮类化合物4的化学结构
本实施例制备终产物4a:White powder,m.p.143.2-143.9℃；Overall yield62％； 1H NMR(CDCl3,400MHz)δ:2.21-2.41(m,3H),2.50-2.65(m,1H),2.91(s,3H),3.15(s,3H),4.87(s,1H),6.42-6.55(m,1H),6.71-6.82(m,1H),6.91-7.01(m,1H),7.12-7.42(m,6H)；13C NMR(CDCl3,100MHz)δ:30.4,33.9,34.1,36.1,53.6,91.5,106.4,118.5,124.9,126.4,126.9,128.8,131.4,146.7,150.8,174.3；HRMS(ESI-TOF)m/z:Calcd.forC19H20N2NaO[M+Na]+:315.1473；Found:315.1475.
本实施例制备终产物4b:White powder,m.p.128.9-129.8℃；Overall yield57％； 1H NMR(CDCl3,400MHz)δ:2.19-2.41(m,6H),2.49-2.61(m,1H),2.90(s,3H),3.15(s,3H),4.87(s,1H),6.45-6.51(m,1H),6.72-6.80(m,1H),6.93-6.99(m,1H),7.03-7.13(m,3H),7.13-7.27(m,2H)；13C NMR(CDCl3,100MHz)δ:21.6,30.4,34.0,34.1,36.1,53.5,91.5,106.4,118.4,123.5,124.9,126.9,127.6,128.6,128.7,131.5,138.3,146.7,150.8,174.4；HRMS(ESI-TOF)m/z:Calcd.for C20H22N2NaO [M+Na]+:329.1629；Found:329.1632.
本实施例制备终产物4c:White powder,m.p.166.2-166.9℃；Overall yield59％； 1H NMR(CDCl3,400MHz)δ:2.20-2.39(m,6H),2.48-2.59(m,1H),2.90(s,3H),3.14(s,3H),4.84(s,1H),6.45-6.50(m,1H),6.72-6.79(m,1H),6.89-6.98(m,1H),7.10-7.20(m,5H)；13C NMR(CDCl3,100MHz)δ:20.9,30.4,33.9,34.2,36.1,53.2,91.7,106.4,118.5,124.8,126.3,128.7,129.4,130.9,131.7,136.6,143.8,150.8,174.4；HRMS(ESI-TOF)m/z:Calcd.for C20H22N2NaO[M+Na]+:329.1629；Found:329.1633.
本实施例制备终产物4d:White powder,m.p.147.2-148.6℃；Overall yield61％； 1H NMR(CDCl3,400MHz)δ:2.28(s,9H),2.31-2.43(m,1H),2.49-2.58(m,3H),2.90(s,3H),4.86(s,1H),6.45-6.50(m,1H),6.74-6.79(m,1H),6.88(s,3H),6.93-7.00(m,1H),7.14-7.21(m,1H)；13C NMR(CDCl3,100MHz)δ:21.5,30.4,34.1,34.3,36.1,53.4,60.4,91.6,106.3,118.4,124.2,125.0,128.6,131.7,138.2,146.7,150.8,174.5；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1784.
本实施例制备终产物4e:Pale yellow oil；Overall yield 60％；1H NMR(CDCl3,400MHz)δ:2.21-2.42(m,6H),2.49-2.60(m,1H),2.88(s,3H),3.12(s,3H),4.84(s,1H),6.30-6.43(m,1H),6.63-6.70(m,1H),6.82-6.90(m,1H),7.15(s,4H)；13C NMR(CDCl3,100MHz)δ:20.8,30.2,33.4,35.0,36.0,53.1,92.1,107.0(d,JCF＝6.4Hz),112.1(d,JCF＝19.3Hz),114.8(d,JCF＝18.5Hz),126.1,129.5,133.5(d,JCF＝5.6Hz),136.9,143.0,147.0,157.1(d,JCF＝187.9Hz),174.0；HRMS(ESI-TOF)m/z:Calcd.for C20H21FN2NaO[M+Na]+:347.1535；Found:347.1536.
本实施例制备终产物4f:Pale yellow oil；Overall yield 60％；1H NMR(CDCl3,400MHz)δ:2.20-2.43(m,6H),2.48-2.62(m,1H),2.89(d,J＝9.2Hz,3H),3.14(d,J＝7.9Hz,3H),4.86(d,J＝4.1Hz,1H),6.39(dd,J＝4.1,8.6Hz,1H),6.69(dd,J＝2.6,8.3Hz,1H),6.82-6.99(m,1H),7.01-7.13(m,3H),7.15-7.28(m,1H)；13C NMR(CDCl3,100MHz)δ:21.6,30.2,33.5,34.9,36.0,53.4,92.0,106.9(d,JCF＝7.9Hz),112.2(d,JCF＝24.2Hz),114.9(d,JCF＝23.1Hz),123.3,126.8,127.8,128.7,133.2(d, JCF＝7.3Hz),138.5,145.9,156.8(d,JCF＝233.4Hz),174.1；HRMS(ESI-TOF)m/z:Calcd.for C20H21FN2NaO[M+Na]+:347.1535；Found:347.1536.
本实施例制备终产物4g:White powder,m.p.157.6-158.2℃；Overall yield60％； 1H NMR(CDCl3,400MHz)δ:2.20-2.42(m,9H),2.48-2.60(m,1H),2.89(d,J＝8.8Hz,3H),3.14(d,J＝8.3Hz,3H),4.86(d,J＝4.3Hz,1H),6.39(dd,J＝4.1,8.6Hz,1H),6.69(dd,J＝2.6,8.3Hz,1H),6.82-7.27(m,4H)；13C NMR(CDCl3,100MHz)δ:21.5,30.3,33.7,34.9,36.0,53.3,53.4,92.0,106.8(d,JCF＝8.0Hz),112.3(d,JCF＝24.1Hz),114.8(d,JCF＝23.1Hz),124.0,128.7,133.4(d,JCF＝7.3Hz),138.3,145.9,147.0,156.8(d,JCF＝234.3Hz),174.2；HRMS(ESI-TOF)m/z:Calcd.for C21H23FN2NaO[M+Na]+:361.1692；Found:361.1694.
本实施例制备终产物4h:White powder,m.p.132.5-133.9℃；Overall yield52％； 1H NMR(CDCl3,400MHz)δ:2.25(s,3H),2.27-2.40(m,3H),2.49-2.60(m,1H),2.88(s,3H),3.13(s,3H),4.82(s,1H),6.38-6.44(m,1H),6.76(s,1H),6.93-7.02(m,1H),7.20-7.39(m,5H)；13C NMR(CDCl3,100MHz)δ:20.8,30.4,33.7,34.8,34.0,53.5,92.0,106.6,125.5,126.4,136.8,128.0,128.7,129.1,131.9,146.7,148.7,174.3；HRMS(ESI-TOF)m/z:Calcd.for C20H22N2NaO[M+Na]+:329.1629；Found:329.1631.
本实施例制备终产物4i:White powder,m.p.164.1-164.9℃；Overall yield61％； 1H NMR(CDCl3,400MHz)δ:2.19-2.41(m,9H),2.47-2.59(m,1H),2.87(s,3H),3.12(s,3H),4.79(s,1H),6.40(d,J＝8.0Hz,1H),6.74(d,J＝1.1Hz,1H),6.91-7.01(m,1H),7.10-7.26(m,4H)；13C NMR(CDCl3,100MHz)δ:20.7,20.8,30.3,33.6,34.8,36.0,53.1,92.1,106.5,125.3,126.3,127.9,129.0,129.3,132.1,136.4,143.8,148.7,174.3；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1789.
本实施例制备终产物4j:Pale yellow oil,Overall yield 65％；1H NMR(CDCl3,400MHz)δ:2.01-2.29(m,4H),2.63(s,3H),2.86-2.91(m,1H),2.95(s,3H),2.99-3.04(m,1H),4.62(s,1H),6.28-6.34(m,1H),6.70-6.77(m,1H),6.86-6.94(m,3H),7.08-7.15(m,1H),7.16-7.27(m,3H)；13C NMR(CDCl3,100MHz)δ:29.9,31.9, 34.6,34.8,47.5,50.0,87.0,106.7,118.2,123.0,126.8,128.0,128.7,130.3,131.9,136.6,150.9,173.5；HRMS(ESI-TOF)m/z:Calcd.for C20H22N2NaO[M+Na]+:329.1629；Found:329.1628.
本实施例制备终产物4k:White crystal,m.p.150.5-151.4℃；Overall yield67％； 1H NMR(CDCl3,400MHz)δ:1.97-2.24(m,4H),2.28(s,3H),2.65(s,3H),2.85(d,J＝13.5Hz,1H),2.97(d,J＝15.4Hz,4H),4.63(s,1H),6.32(d,J＝7.8Hz,1H),6.73(t,J＝7.4Hz,1H),6.80(d,J＝7.9Hz,2H),6.91(d,J＝7.0Hz,1H),7.01(d,J＝7.8Hz,2H),7.10-7.14(m,1H)；13C NMR(CDCl3,100MHz)δ:20.9,29.8,31.7,34.5,34.8,46.8,49.8,86.9,106.5,118.1,123.0,128.5,130.1,131.9,133.3,136.2,150.7,173.6；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1786.
本实施例制备终产物4l:White powder,m.p.139.7-140.3℃；Overall yield64％； 1H NMR(CDCl3,400MHz)δ:1H NMR(CDCl3,400MHz)δ(ppm):1.99(s,3H),2.03-2.27(m,4H),2.80(s,3H),2.92(d,J＝13.8Hz,1H),3.00(s,3H),3.08(d,J＝13.7Hz,1H),4.60(s,1H),6.36(d,J＝7.8Hz,1H),6.61-6.69(m,2H),6.83-7.15(m,5H)；13C NMR(CDCl3,100MHz)δ:19.8,29.7,31.1,34.8,43.0,50.2,87.6,106.5,118.1,123.1,125.4,126.7,128.6,130.4,131.4,134.9,137.2,150.5,173.4；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1789.
本实施例制备终产物4m:Pale yellow oil；Overall yield 65％；1H NMR(CDCl3,400MHz)δ:2.06-2.28(m,7H),2.64(s,3H),2.84-2.88(m,1H),2.93-3.00(m,4H),4.63(s,1H),6.30-6.34(m,1H),6.67(s,1H),6.70-6.78(m,2H),6.90-6.94(m,1H),6.98-7.03(m,1H),7.07-7.15(m,2H)；13C NMR(CDCl3,100MHz)δ:21.3,29.9,31.6,34.6,34.8,47.4,49.9,86.9,106.6,118.2,123.0,127.4,127.8,128.6,131.1,132.0,136.4,137.5,150.9,173.6；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1786.
本实施例制备终产物4n:White powder,m.p.124.6-125.5℃；Overall yield60％； 1H NMR(CDCl3,400MHz)δ:2.01-2.25(m,4H),2.70(s,3H),2.87-2.95(m,4H),3.10-3.19(m,1H),3.78(s,3H),4.77(s,1H),6.30-6.35(m,1H),6.69-6.79(m,3H), 6.83-6.88(m,1H),6.95-7.00(m,1H),7.07-7.13(m,1H),7.14-7.27(m,1H)；13CNMR(CDCl3,100MHz)δ:30.0,31.7,34.7,34.9,39.8,50.3,55.1,87.0,106.5,110.4,118.1,120.2,123.2,128.0,128.4,132.1,132.6,150.8,157.5,173.8；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO2[M+Na]+:359.1735；Found:359.1739.
本实施例制备终产物4o:Pale yellow oil；Overall yield 61％；1H NMR(CDCl3,400MHz)δ:1.97-2.31(m,4H),2.66(s,3H),2.80-2.88(m,1H),2.91-3.00(m,4H),3.76(s,3H),4.61(s,1H),6.32(d,J＝7.8Hz,1H),6.69-6.77(m,3H),6.78-6.85(m,2H),6.90(dd,J＝0.9,7.4Hz,1H),7.08-7.28(m,1H)；13C NMR(CDCl3,100MHz)δ:29.9,31.8,34.7,34.9,46.5,50.0,55.1,87.0,106.6,113.3,118.1,123.0,128.6,131.2,131.9,150.9,158.4,173.6；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO2[M+Na]+:359.1735；Found:359.1736.
本实施例制备终产物4p:Pale yellow oil；Overall yield 63％；1H NMR(CDCl3,400MHz)δ:2.07-2.24(m,4H),2.70(s,3H),2.89-2.97(m,4H),3.01-3.07(m,1H),3.77(s,3H),3.86(s,3H),4.87(s,1H),6.28-6.37(m,2H),6.73-6.79(m,2H),6.81-6.86(m,1H),6.99-7.04(m,1H),7.08-7.14(m,1H)；13C NMR(CDCl3,100MHz)δ:29.9,31.5,34.7,34.8,39.9,50.4,55.6,64.1,86.4,106.6,110.9,118.1,122.8,123.3,123.8,128.5,130.4,132.5,147.4,150.8,152.7,173.8；HRMS(ESI-TOF)m/z:Calcd.for C22H26N2NaO3[M+Na]+:389.1841；Found:389.1846.
本实施例制备终产物4q:Pale yellow oil；Overall yield 62％；1H NMR(CDCl3,400MHz)δ:2.00-2.03(m,1H),2.12-2.30(m,3H),2.56(s,3H),2.75-2.80(m,1H),3.98-3.03(m,4H),3.56(s,3H),3.83(s,3H),4.57(s,1H),6.04-6.09(m,1H),6.26-6.31(m,1H),6.56-6.60(m,1H),6.72-6.79(m,2H),6.95-6.99(m,1H),7.09-7.14(m,1H)；13C NMR(CDCl3,100MHz)δ:29.9,32.1,34.8,34.9,47.2,50.2,55.4,55.8,86.7,106.9,110.4,113.0,118.1,122.2,123.1,128.7,129.2,131.6,147.8,148.2,151.4,173.5；HRMS(ESI-TOF)m/z:Calcd.for C22H26N2NaO3[M+Na]+:389.1841；Found:389.1842.
本实施例制备终产物4r:Pale yellow oil；Overall yield 61％；1H NMR(CDCl3,400MHz)δ:1.99-2.21(m,4H),2.72(s,3H),2.86(d,J＝13.6Hz,1H),2.96(s,3H), 3.04(d,J＝13.6Hz,1H),3.76(s,6H),4.74(s,1H),6.23-6.36(m,2H),6.44(d,J＝2.4Hz,1H),6.67(d,J＝8.3Hz,1H),6.74(dd,J＝0.8,7.4Hz,1H),6.96(dd,J＝0.8,7.3Hz,1H),7.05-7.14(m,1H)；13C NMR(CDCl3,100MHz)δ:30.0,31.7,34.8,35.0,39.2,50.3,55.0,55.2,87.0,98.3,103.8,106.5,117.5,118.0,123.0,132.5,150.8,158.4,159.6,173.9；HRMS(ESI-TOF)m/z:Calcd.for C22H26N2NaO3[M+Na]+:389.1841；Found:389.1843.
本实施例制备终产物4s:White powder,m.p.155.5-156.1℃；Overall yield64％； 1H NMR(CDCl3,400MHz)δ:2.02-2.29(m,4H),2.57(s,3H),2.73-2.77(m,1H),3.00(s,3H),3.10-3.16(m,1H),3.47(s,3H),3.80(s,3H),3.85(s,3H),4.66(s,1H),6.00(s,1H),6.24-6.30(m,1H),6.50(s,1H),6.73-6.78(m,1H),6.99-7.12(m,2H)； 13C NMR(CDCl3,100MHz)δ:29.9,32.1,34.8,35.0,39.4,50.5,55.9,56,0,56.1,86.5,96.9,106.8,115.1,116.5,118.0,122.9,128.5,132.0,142.1,147.9,151.4,151.5,173.5；HRMS(ESI-TOF)m/z:Calcd.for C23H28N2NaO4[M+Na]+:419.1946；Found:419.1948.
本实施例制备终产物4t:White powder,m.p.150.4-151.4℃；Overall yield63％； 1H NMR(CDCl3,400MHz)δ:2.08-2.28(m,4H),2.76(s,3H),2.89-2.94(m,1H),2.98-3.03(m,4H),3.83-3.86(m,6H),3.89(s,3H),4.88(s,1H),6.35-6.38(m,1H),6.46-6.53(m,2H),6.75-6.81(m,1H),7.01-7.05(m,1H),7.12-7.17(m,1H)；13CNMR(CDCl3,100MHz)δ:24.1,30.0,31.8,34.9,40.0,50.4,55.9,60.8,64.3,86.7,106.8,118.2,122.5,122.9,126.2,128.6,132.6,142.1,150.9,152.2,152.5,174.1；HRMS(ESI-TOF)m/z:Calcd.forC23H28N2NaO4[M+Na]+:419.1946；Found:419.1950.
本实施例制备终产物4u:Pale yellow oil；Overall yield 57％；1H NMR(CDCl3,400MHz)δ:2.06-2.27(m,4H),2.63(s,3H),2.81-2.86(m,1H),2.97(s,3H),3.13-3.18(m,1H),3.53(s,3H),3.77(s,3H),4.74(s,1H),6.18-6.20(m,1H),6.28-6.32(m,1H),6.66-6.70(m,1H),6.73-6.80(m,2H),7.00-7.04(m,1H),7.08-7.12(m,1H)；13C NMR(CDCl3,100MHz)δ:30.0,31.9,34.8,34.9,40.0,50.4,55.4,55.7,86.7,106.7,111.4,113.1,117.2,118.1,122.9,126.2,128.5,132.3,151.1,151.7,152.8,173.7.HRMS(ESI-TOF)m/z:Calcd.for C22H26N2NaO3[M+Na]+: 389.1841；Found:389.1843.
本实施例制备终产物4v:Pale yellow oil；Overall yield 56％；1H NMR(CDCl3,400MHz)δ:1.28(s,9H),2.02-2.28(m,4H),2.63(s,3H),2.84-2.98(m,5H),4.62(s,1H),6.30-6.34(m,1H),6.71-6.77(m,1H),6.82-6.87(m,2H),6.91-6.96(m,1H),7.09-7.15(m,1H),7.20-7.27(m,2H)；13C NMR(CDCl3,100MHz)δ:29.9,31.3,31.8,34.3,34.5,34.7,46.8,49.9,86.9,106.6,118.2,123.0,124.8,128.6,129.9,132.2,133.4,149.7,150.8,173.6；HRMS(ESI-TOF)m/z:Calcd.for C24H30N2NaO[M+Na]+:385.2255；Found:385.2257.
本实施例制备终产物4w:White powder,m.p.95.2-95.9℃；Overall yield 64％；1H NMR(CDCl3,400MHz)δ:1.19-1.22(m,6H),2.06-2.28(m,4H),2.64(s,3H),2.81-2.90(m,2H),2.92(s,3H),2.94-2.99(m,1H),4.62(s,1H),6.30-6.35(m,1H),6.72-6.77(m,1H),6.81-6.85(m,2H),6.90-6.95(m,1H),7.04-7.09(m,2H),7.10-7.15(m,1H)；13C NMR(CDCl3,100MHz)δ:23.9,24.0,29.9,31.7,33.6,34.6,34.8,46.9,49.9,86.9,106.6,118.2,123.0,126.0,128.6,130.2,132.2,133.7,147.4,150.8,173.6；HRMS(ESI-TOF)m/z:Calcd.forC23H28N2NaO[M+Na]+:371.2099；Found:371.2097.
本实施例制备终产物4x:White powder,m.p.140.0-140.7℃；Overall yield62％； 1H NMR(CDCl3,400MHz)δ:2.05-2.30(m,4H),2.64(s,3H),2.87(d,J＝13.4Hz,1H),2.97(s,3H),3.01(d,J＝13.4Hz,1H),4.59(s,1H),6.32(d,J＝7.9Hz,1H),6.51-6.55(m,1H),6.68(d,J＝7.7Hz,1H),6.73-6.79(m,1H),6.86-6.94(m,2H),7.10-7.22(m,2H)；13CNMR(CDCl3,100MHz)δ:29.7,31.5,34.6,34.8,47.1,49.9,86.8,106.7,113.5,116.8(d,JCF＝21.1Hz),118.3,122.9,125.8(d,JCF＝2.8Hz),128.9,129.2,138.9(d,JCF＝7.2Hz),150.7,162.3(d,JCF＝244.5Hz),173.5；HRMS(ESI-TOF)m/z:Calcd.for C20H21FN2NaO[M+Na]+:347.1535；Found:347.1539.
本实施例制备终产物4y:Pale yellow oil；Overall yield 63％；1H NMR(CDCl3,400MHz)δ:2.04-2.30(m,4H),2.61(s,3H),2.93(d,J＝13.2Hz,1H),2.98(s,3H),3.08(d,J＝13.3Hz,1H),4.58(d,J＝7.5Hz,1H),6.31(d,J＝7.8Hz,1H),6.76(t,J＝7.4Hz,1H),6.85-7.00(m,3H),7.11-7.15(m,1H),7.42-7.56(m,2H)；13C NMR (CDCl3,100MHz)δ:29.7,31.6,34.5,34.9,47.2,50.0,86.8,106.8,118.3,122.9,124.7,124.8,128.8,129.0,130.5,130.9,130.7,130.4,132.2,140.7,150.8,167.7,173.3；HRMS(ESI-TOF)m/z:Calcd.for C21H21F3N2NaO[M+Na]+:397.1503；Found:397.1506.
本实施例制备终产物4z:White powder,m.p.126.8-127.7℃；Overall yield64％； 1H NMR(CDCl3,400MHz)δ:2.00-2.31(m,4H),2.69(s,3H),3.00(s,3H),3.17(d,J＝14.8Hz,1H),3.24(d,J＝14.7Hz,1H),4.62(s,1H),6.36(d,J＝7.9Hz,1H),6.65(d,J＝3.1Hz,1H),6.74-6.79(m,1H),6.86-6.89(m,1H),7.00-7.05(m,1H),7.06-7.12(m,1H),7.14-7.17(m,1H)；13C NMR(CDCl3,100MHz)δ:30.0,33.0,34.6,35.4,41.3,49.7,86.9,106.6,118.4,122.9,124.6,126.4,127.2,128.9,131.5,138.4,151.2,174.0；HRMS(ESI-TOF)m/z:Calcd.for C18H20N2NaOS[M+Na]+:335.1194；Found:335.1190.
本发明的式(1)六氢吡啶-2,3-并吲哚-2-酮类化合物具有重要的生物活性，体外对人肺癌细胞(A549),人白血病细胞(K562),以及体外对人前列腺(PC-3)共三株肿瘤细胞的细胞毒性试验表明：此类式(1)所示的结构的六氢吡啶-2,3-并吲哚-2-酮类化合物对肿瘤细胞生长具有抑制作用，有可能发展成为新的防治肿瘤药物或防治肿瘤药物中间体。必须说明，本发明的药理实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护否认范围。
药理实施例1：化合物4i、4k、4o、4r、4u、4v或4w对A549细胞的细胞毒性
A549(人非小细胞肺癌肺癌)用DMEM培养基培养，培养基中含10％的胎牛血清，100U/mL的青霉素和100U/mL链霉素。细胞以每孔4000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。细胞经过24小时的孵育后，分别将新配的化合物4i、4k、4o、4r、4u、4v或4w的二甲基亚砜溶液以浓度梯度加入到各孔中，使孔中化合物最终浓度分别为6.25μmol/L,12.5μmol/L,25μmol/L,50μmol/L和100μmol/L。48小时后，每孔加入10μL MTT(5mg/mL)的磷酸盐 缓冲液，再继续在37℃培养4小时后，离心5分钟除去未转化的MTT，每孔中加入150μL二甲基亚砜。以溶解还原的MTT晶体甲臜(formazan)，用酶标仪在490nm波长测定OD值。其中化合物4i、4k、4o、4r、4u、4v或4w对A549细胞半抑制浓度IC50由spss软件(19版本)分析得到。化合物4i对A549肿瘤细胞的IC50为7.23μmol/L；化合物4k对A549肿瘤细胞的IC50为17.34μmol/L；化合物4o对A549肿瘤细胞的IC50为7.41μmol/L；化合物4r对A549肿瘤细胞的IC50为9.36μmol/L；化合物4u对A549肿瘤细胞的IC50为5.65μmol/L；化合物4v对A549肿瘤细胞的IC50为18.17μmol/L；化合物4w对A549肿瘤细胞的IC50为12.65μmol/L；而阳性对照顺铂对A549肿瘤细胞的IC50为28.4μmol/L。
实验结论：A549细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的六氢吡啶-2,3-并吲哚-2-酮类化合物对A549细胞具有较强的细胞毒性，和肿瘤治疗一线用药顺铂同一数量级或活性比顺铂更好，有可能发展成新的具有抗肿瘤作用的药物。
药理实施例2：化合物4i、4q、4r、4u、4v、4w或4k对K562细胞的细胞毒性
K562(人慢性髓系白血病细胞)用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100U/mL的青霉素和100U/mL链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。具体方法如药理实施例1。化合物4i对K562肿瘤细胞的IC50为32.86μmol/L；化合物4q对K562肿瘤细胞的IC50为52.97μmol/L；化合物4r对K562肿瘤细胞的IC50为54.56μmol/L；化合物4v对K562肿瘤细胞的IC50为27.99μmol/L；化合物4w对K562肿瘤细胞的IC50为35.54μmol/L；化合物4k对K562肿瘤细胞的IC50为45.81μmol/L；而阳性对照顺铂对K562肿瘤细胞的IC50为27.4μmol/L。
实验结论：K562细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的六氢吡啶-2,3-并吲哚-2-酮类化合物对K562细胞具有较强的细胞毒性，和肿瘤治疗一线用药顺铂同一数量级或活性比顺铂更好，有可能发展成新的具有抗肿瘤作用的药物或中间体。
药理实施例3：化合物4i、4o、4q、4r、4u、4v、4w或4k对PC-3细胞的细胞毒性
PC-3(人前列腺癌)细胞用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100U/mL青霉素及100U/mL的链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。具体方法如药理实施例1。化合物4i对PC-3肿瘤细胞的IC50为9.10μmol/L；化合物4o对PC-3肿瘤细胞的IC50为17.56μmol/L；化合物4q对PC-3肿瘤细胞的IC50为23.27μmol/L；化合物4r对PC-3肿瘤细胞的IC50为15.90μmol/L；化合物4u对PC-3肿瘤细胞的IC50为27.05μmol/L；化合物4v对PC-3肿瘤细胞的IC50为29.20μmol/L；化合物4w对PC-3肿瘤细胞的IC50为17.19μmol/L；化合物4k对PC-3肿瘤细胞的IC50为46.12μmol/L；而阳性对照顺铂对PC-3肿瘤细胞的IC50为26.2μmol/L。
实验结论：PC-3细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的六氢吡啶-2,3-并吲哚-2-酮类化合物对PC-3细胞具有较强的细胞毒性，和肿瘤治疗一线用药顺铂同一数量级或活性比顺铂更好，有可能发展成新的具有抗肿瘤作用的药物。
从以上药理实施例中我们可以看出这些六氢吡啶-2,3-并吲哚-2-酮类化合物对这三株肿瘤细胞都显示有一定的细胞毒性。可见这些化合物具有开发成为抗肿瘤药物或中间体的潜力，值得继续深入研究下去。

Claims (3)

1.一种具有抑制肿瘤生长活性的六氢吡啶-2,3-并吲哚-2-酮类化合物，其特征在于：该化合物具有如通式(I)所示的结构：
具体为如下结构式：
2.一种如权利要求1所述的六氢吡啶-2,3-并吲哚-2-酮类化合物的制备方法，其特征在于：由相应的3-单取代氧化吲哚1与丙烯酸酯2先发生Michael加成反应，生成中间体3，然后中间体3氮原子脱保护基团Boc得到了中间体3-1，然后中间体3-1氮原子上保护基甲基得到中间体3-2,中间体3-2再与甲胺发生酰胺化反应，生成中间体3-3，最后中间体3-3通过与四氢化铝锂发生氢化还原环化反应生成最终产物六氢吡啶-2,3-并吲哚-2-酮类化合物。
合成路线如下：
R4为烷基。
3.一种如权利要求1所述的六氢吡啶-2,3-并吲哚-2-酮类化合物在制备防治肿瘤疾病药物中的应用。
CN201510611722.5A 2015-09-24 2015-09-24 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用 Active CN105254626B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510611722.5A CN105254626B (zh) 2015-09-24 2015-09-24 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510611722.5A CN105254626B (zh) 2015-09-24 2015-09-24 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用

Publications (2)

Publication Number Publication Date
CN105254626A CN105254626A (zh) 2016-01-20
CN105254626B true CN105254626B (zh) 2018-02-23

Family

ID=55094613

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510611722.5A Active CN105254626B (zh) 2015-09-24 2015-09-24 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用

Country Status (1)

Country Link
CN (1) CN105254626B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107759598B (zh) * 2016-08-16 2019-09-17 南方科技大学 含氮桥环的中环化合物及其制备方法和应用
CN107235969B (zh) * 2017-08-04 2021-07-06 贵州大学 合成六氢吡啶-2,3-并吲哚-2-酮骨架化合物的关键中间体及其制备方法及应用
CN108299491B (zh) * 2018-03-26 2020-09-11 广东工业大学 3-双烷基化-2-吲哚酮衍生物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188302A1 (en) * 2012-06-13 2013-12-19 E. I. Du Pont De Nemours And Company Thermoplastic melt-mixed composition with amino acid heat stabilizer

Also Published As

Publication number Publication date
CN105254626A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
Yoshida et al. Synthesis of γ-benzopyranone by TfOH-promoted regioselective cyclization of o-alkynoylphenols
CN102040625B (zh) 手性螺环吡啶胺基膦配体化合物与合成方法及其应用
Arancibia et al. Synthesis and antimalarial activities of rhenium bioorganometallics based on the 4-aminoquinoline structure
Fang et al. Ferulic acid–carbazole hybrid compounds: combination of cholinesterase inhibition, antioxidant and neuroprotection as multifunctional anti-Alzheimer agents
CN105254626B (zh) 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用
Jiang et al. Novel chromanone-dithiocarbamate hybrids as multifunctional AChE inhibitors with β-amyloid anti-aggregation properties for the treatment of Alzheimer’s disease
Petasis et al. Synthesis of 2H-chromenes and 1, 2-dihydroquinolines from aryl aldehydes, amines, and alkenylboron compounds
CN104557602B (zh) 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用
CN107383030B (zh) 姜黄酮拼接3,3’-吡咯双螺环氧化吲哚化合物及其制备方法及应用
Liu et al. DABCO-catalyzed sp3 C–H activation: rapid access to isoxazole or coumarin-fused 3-quaternary carbon oxindoles and isoxazole-fused pyrrolidinones
CN112707833A (zh) 组蛋白去乙酰酶抑制剂及其制备和应用
CN107382820B (zh) 一种3-芳基异吲哚衍生物的合成方法
Gabriele et al. Tandem catalysis in ionic liquids: a recyclable catalytic synthesis of benzofuran derivatives
Wiegerinck et al. Semisynthesis of some 7-deoxypaclitaxel analogs from taxine B
CN103073559B (zh) 手性芳香螺缩酮类化合物及其制备方法和应用
CN111892608A (zh) 一种具有光学活性的螺杂环2,3-二氢苯并呋喃类化合物及其应用
CN104771392A (zh) 一类组蛋白去乙酰化酶抑制剂及应用
Meiresonne et al. Synthesis of novel β-aminocyclobutanecarboxylic acid derivatives by a solvent-free aza–Michael addition and subsequent ring closure
Chen et al. Efficient capture of difluorocarbene by pyridinium 1, 4-zwitterionic thiolates: A concise synthesis of difluoromethylene-containing 1, 4-thiazine derivatives
CN103804273B (zh) 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法
CN108299291B (zh) 酰基化喹啉或异喹啉衍生物的合成方法
CN105693662A (zh) 一种乙酰胆碱酯酶抑制剂组合物及其制备方法与应用
CN106038560A (zh) 一类含硫穿心莲内酯衍生物在制备治疗前列腺癌药物中的应用
Mayer et al. Synthesis of novel steroid analogues containing nitrile and disulfide moieties via palladium-catalyzed cross-coupling reactions
WO2010093615A2 (en) Compounds, their syntheses, compositions, and methods to treat cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant